Recordati
engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases... Read moreRecordati
engages in the research, development, manufacture, marketing and sale of pharmaceutical drugs for the treatment of rare diseases... Read more
News
Apr 16, 2025
FinanzNachrichten
Recordati: Recordati: RECORDATI: FDA GRANTS ISTURISA (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME
Mar 28, 2025
Marketscreener
Recordati: Recordati : 28 March 2025 - Directors' Report on item 1 on the agenda - Financial statements approval and allocation of profit
Mar 20, 2025
Marketscreener
Recordati: Recordati : 20 March 2025 - Directors' Report on item 2 on the agenda - Appointment of the Board of Directors
Feb 20, 2025
Owler
Recordati S.p.A.: Recordati's employee count changed from 4.30K in Dec 2023 to 4.45K in Dec 2024
Feb 13, 2025
FinanzNachrichten
Recordati: Recordati: RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
Jan 10, 2025
Owler
Recordati S.p.A.: Recordati's revenue changed from $2.44B in Jun 2024 to $2.52B in Sep 2024
Nov 29, 2024
Marketscreener
Recordati: Recordati takes over Enjaymo and expects strong revenue boost
Nov 27, 2024
Private Equity Wire
Recordati: CVC explores sale of drug maker Recordati, says rival CEO
Nov 11, 2024
Yahoo
Recordati: Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Nov 08, 2024
Marketscreener
Recordati: Recordati launches buyback and confirms guidance after results
Recordati Competitors
1
2
3
4
5
6
7
8
9
10